Advertisement
Advertisement
U.S. markets close in 5 hours 24 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Awakn Life Sciences Corp. (AWKN.NE)

NEO - NEO Real Time Price. Currency in CAD
Add to watchlist
2.05000.0000 (0.00%)
As of 10:06AM EST. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.0500
Open2.0500
Bid2.0000 x N/A
Ask2.0500 x N/A
Day's Range2.0500 - 2.0500
52 Week Range1.5000 - 3.3500
Volume425
Avg. Volume37,920
Market Cap50.618M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.6460
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for AWKN.NE

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Newsfile

      Awakn Life Sciences Files Patent Application for a New Class of Entactogen-Like Molecules to Treat a Broad Range of Addictions

      Novel Entactogen NCE Series Enhances the Potential for Improved Treatment of Addiction Toronto, Ontario--(Newsfile Corp. - January 26, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing and delivering psychedelic therapeutics to treat addiction, announces the filing of a patent application for a new chemical series of entactogen-like molecules, further strengthening Awakn's intellectual property portfolio and pipeli

    • Market Exclusive

      Weekly Roundup on the Cannabis Sector & Psychedelic Sector

      Key Takeaways; Cannabis Sector Curaleaf completed the $210 million acquisition of Bloom Dispensaries in Arizona. Canadian retail cannabis sales fell 3% from October in November, rising 36% from a year ago. Key Takeaways; Psychedelic Sector Awakn signs MOU with MAPS: The company also announced publication of paper; “Debunking the myth of ‘Blue Mondays’.” Numinus announced […] The post Weekly Roundup on the Cannabis Sector & Psychedelic Sector appeared first on Market Exclusive.

    • Newsfile

      Awakn Life Sciences Signs MOU with Maps

      Agreement to Explore a Partnership for MDMA-Assisted Therapy for Treatment of Alcohol Use Disorder in Europe Toronto, Ontario--(Newsfile Corp. - January 19, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat Addiction, announced today it has signed a Memorandum of Understanding ("MOU") with the Multidisciplinary Association for Psychedelic Studies (MAPS) t

    Advertisement
    Advertisement